Am J Transl Res. 2026 Oct 15;18(10):9421-9433. doi: 10.62347/PSQU7272. eCollection 2026.
ABSTRACT
PURPOSE: Idiopathic Granulomatous mastitis (IGM) is a chronic inflammatory breast disease for which conventional corticosteroid therapy is limited by substantial adverse effects. This study aimed to compare the analgesic efficacy, quality-of-life improvement, and safety of low-intensity focused ultrasound (LIFU) monotherapy versus intralesional corticosteroid injections in patients with IGM.
METHODS: This retrospective study included individuals diagnosed with IGM between September 2021 and December 2025. Patients received either intralesional corticosteroid injections (hormone group, n = 124) or low-intensity focused ultrasound monotherapy (LIFU group, n = 117). Primary outcomes were pain intensity on the 10-cm Visual Analog Scale (VAS) and health-related quality of life using the 36-Item Short Form Health Survey (SF-36). Secondary outcomes included overall clinical response, inflammatory markers, ultrasound lesion characteristics and volume reduction rate, adverse events, and recurrence.
RESULTS: At week 12, the LIFU group had significantly lower VAS pain scores (2.86 ± 0.74 vs. 3.52 ± 0.86, P < 0.001). Improvements were also observed across other SF-36 domains, with six of eight domains remaining significant after correction for multiple comparisons. The overall response rate (ORR) in LIFU group was 94.02%, which was significantly higher than the 83.87% observed in the corticosteroid group (P = 0.013). Inflammatory markers were markedly lower with LIFU (CRP: 7.12 ± 2.37 vs. 8.96 ± 2.98 mg/L, P < 0.001; ESR: 16.92 ± 5.61 vs. 19.34 ± 6.44 mm/h, P = 0.002), and lesion volume reduction was greater (60.12 ± 11.95% vs. 55.26 ± 12.48%, P = 0.002). Adverse event rates (10.26% vs. 25.00%, P = 0.003) and recurrence rates (7.89% vs. 29.03%, P = 0.001) were both significantly lower in the LIFU group.
CONCLUSION: Low-intensity focused ultrasound monotherapy is associated with superior pain relief, greater improvement in quality of life, higher clinical response rates, and a more favorable safety profile than corticosteroid injections in patients with IGM.
PMID:43068092 | PMC:PMC13788513 | DOI:10.62347/PSQU7272